This study compared fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH) for determining HER2/neu gene amplification status in 188 breast cancer samples using tissue microarray technology. The results showed a high concordance rate of 94.1% between FISH and CISH. Both methods identified HER2/neu amplification in around 24% of samples. The study concluded that CISH is a feasible and cost-effective alternative to FISH for assessing HER2/neu amplification in breast cancer.
This is a journal article review of Multiplex chip protocol used for prostate biopsy. It also includes a modern concept of human molecular genetics called CRISPR-Cas9
Modeling the Dynamics of Glioblastoma Multiforme and Cancer Stem CellsStephen Steward
In this talk, we extend the work of Kronik, Kogan, Vainstein, and Agur (2008) by incorporating the cancer stem cell hypothesis into a treatment model for Glioblastoma Multiforme. Cancer Stem Cells (CSCs) are a specialized form of tumor cell with normal adult stem cell properties. CSCs are believed to be one of the primary reasons for cancer recurrence since they are more resilient to current treatment practices and are able to repopulate the tumor. We present a system of nonlinear ordinary differential equations that describes the interaction between cancer stem cells, tumor cells, and alloreactive cytotoxic-T-lymphocytes (CTLs). Under the assumption of constant treatment, we present conditions on the treatment amount that leads to a locally stable cure state. We also explore a more biologically accurate treatment schedule in which CTLs are injected periodically. In the case of periodic treatment, we numerically establish treatment schedules that lead to cancer persistence, cancer recurrence, and cancer eradication. We conclude with a sensitivity analysis of our parameters and a discussion of biological implications.
Brain Metastasis: Emerging Treatments ans Reasons to be Hopefulbkling
Join Dr. Nancy Lin, Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute, as she discusses diagnosis, symptom management, emerging treatments and reasons to be hopeful with Julia Maues, a metastatic breast cancer patient advocate. This one-hour webinar will allow time for questions from participants. In collaboration with Living Beyond Breast Cancer and Young Survival Coalition.
This is a journal article review of Multiplex chip protocol used for prostate biopsy. It also includes a modern concept of human molecular genetics called CRISPR-Cas9
Modeling the Dynamics of Glioblastoma Multiforme and Cancer Stem CellsStephen Steward
In this talk, we extend the work of Kronik, Kogan, Vainstein, and Agur (2008) by incorporating the cancer stem cell hypothesis into a treatment model for Glioblastoma Multiforme. Cancer Stem Cells (CSCs) are a specialized form of tumor cell with normal adult stem cell properties. CSCs are believed to be one of the primary reasons for cancer recurrence since they are more resilient to current treatment practices and are able to repopulate the tumor. We present a system of nonlinear ordinary differential equations that describes the interaction between cancer stem cells, tumor cells, and alloreactive cytotoxic-T-lymphocytes (CTLs). Under the assumption of constant treatment, we present conditions on the treatment amount that leads to a locally stable cure state. We also explore a more biologically accurate treatment schedule in which CTLs are injected periodically. In the case of periodic treatment, we numerically establish treatment schedules that lead to cancer persistence, cancer recurrence, and cancer eradication. We conclude with a sensitivity analysis of our parameters and a discussion of biological implications.
Brain Metastasis: Emerging Treatments ans Reasons to be Hopefulbkling
Join Dr. Nancy Lin, Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute, as she discusses diagnosis, symptom management, emerging treatments and reasons to be hopeful with Julia Maues, a metastatic breast cancer patient advocate. This one-hour webinar will allow time for questions from participants. In collaboration with Living Beyond Breast Cancer and Young Survival Coalition.
Hypofractionation in early breast cancer is no more a research scholars topic. Multiple studies with robust data have proven its utility. It may hold an important role in many countries with constrained resources. This is a short presentation incorporating important completed and ongoing trials. Feel free to use this.
Hypofractionation in early breast cancer is no more a research scholars topic. Multiple studies with robust data have proven its utility. It may hold an important role in many countries with constrained resources. This is a short presentation incorporating important completed and ongoing trials. Feel free to use this.
Folio Biosciences' tissue microarray product line enhances research by providing multiple patients on one array. This presentation goes into detail on how the microarrays are made and Folio's capabilities in this area.
HETEROGENEITY OF C ERB B FAMILY MEMBERS EXPRESSION IS RELATED TO CELL MORPHOL...ANCA MARIA CIMPEAN
ABSTRACT
Purpose. Epidermal growth factor receptor (EGFR, HER1) and human epidermal receptor 2 (HER2) assessement in pituitary adenomas related to hormone profile. Design and methods. For 60 retrospective cases of pituitary adenomas, we established the histopathologic diagnosis by using morphological stains, followed by case selection for immunoprofile and EGFR and HER 2 assessement. Results. More than one third of the studied pituitary adenomas (33,33%) were positive for HER2, with membranar pattern in basophilic cells and with predominantly cytoplasmic, granular pattern for acidophils cells. HER2 immuno-expression characterized PRL secreting adenomas (p=0.005) and associations between FSH-LH (p< 0.001) TSH-FSH (p=0,024) and TSH-LH (p=0.028). In situ hybridization confirmed HER2 gene amplification in 33,34% out of all positive cases for HER2 by immunohistochemistry. EGFR positivity was found significantly for GH-prolactin (p=0.000) and prolactin-ACTH (p=0.045) co-expressing pituitary adenomas, peritumoral macrophages and folliculostellate cells. Conclusions. Differential HER2 and EGFR expression related to hormone profile heterogeneity can define different subclasses of pituitary adenomas and could explain clinical, prognostic and therapeutic heterogeneity which are observed in clinical practice. Our results support re-classification of pituitary adenomas based on molecular approach which should include markers with well certified prognostic and therapeutic impact.
Key Words: HER2, EGFR,pituitary adenomas, targeted therapy
A Novel Immunohistochemical Signature with the Quantification of HER2 Predict...Premier Publishers
Around 30% of HER2-positive breast cancer patients do not respond to neoadjuvant chemotherapy (NAC) and anti-HER2 drugs. It is necessary to improve the selection system of patients who will benefit from this treatment, with others biomarkers that could also predict the response. HER2, ki67, ER, PR, LC45 and the HER family were quantified by immunochemistry in HER2+ breast tumors from 99 patients treated with NAC and anti-HER2 drugs. The correlation between the expression of these proteins and the response rate was evaluated through both an area under the ROC curve and a logistic regression model analysis. HER2 score 3+ is a poor predictive biomarker to NAC with anti-HER2 drugs, with an area under the ROC curve (AUCROC) HER2 score 3+ of 0.719. HER2 score 2+ with a curve of 0.438, is not associated with a response rate of treatment. The optimal HER2 score 3+ cutoff point has been proven to yield 21% in HER2-enriched tumors and 10% in HER2-luminal ones. The signature (AUC=0.809) formed by a high percentage of HER2 score 3+, a high percentage of Ki67, a low Histo-score of ER and the absence of involvement lymph nodes is a better predictive combination for response than HER2 score 3+ alone. HER2 status is a poor clinical biomarker. Our proposed signature will improve the selection of patients who benefit from the neoadjuvant treatment.
The Level of Expression of Ki-67 in Invasive Cervical Cancers and Cervical I...Crimsonpublishers-IGRWH
The Level of Expression of Ki-67 in Invasive Cervical Cancers and Cervical Intraepithelial Neoplasia in Ghanaian Women by Ama Afrah in Womens Health Journal
Гостевая лекция Института биоинформатики. Подробнее: http://bioinformaticsinstitute.ru/lectures/1218
Несмотря на несерьезное название, на лекции разговор пойдет о важной проблеме в работе биоинформатика, почти любая реальная задача которого связана с обработкой и анализом больших данных. И решить задачу нужно не только правильно, но и эффективно. Процесс решения можно условно разделить на две части: «придумать», как решать, и «обучить» этому компьютер. И на лекции речь пойдет именно об эффективном «обучении».
Наивно реализованные алгоритмы работают неприемлемо долго, когда дело доходит до гигабайтов реальных данных. От биоинформатика уже требуются не просто базовые навыки программирования, но и знание технических нюансов. И даже у профессионального программиста уйдет немало времени, например, чтобы выгодно использовать возможности Hadoop при работе с Big Data. Так можно ли современному ученому обойтись без тщательного изучения кучи языков, библиотек и фреймворков и сосредоточиться именно на решении?
Ядерный век прошел, и становится все понятнее, что в фокусе науки 21-го века будут живые системы, медицина, и человек во всех его проявлениях. Здесь осуществляются самые масштабные финансовые вливания, и на эту отрасль человечество возлагает самые большие надежды. Все чаще слышатся предметные обсуждения тем, казавшихся еще недавно научной фантастикой: сможет ли человечество победить старение, рак, и другие смертельные заболевания? Сможет ли менять свой геном по собственному желанию? Будем ли мы хозяевами своим телам в той же мере, как мы хозяйничаем на Земле?
Многие десятилетия биология и медицина развивались как описательные науки. Однако по мере созревания и накопления информации, любая наука рано или поздно переходит на более точный язык - язык математики. Проект "Геном человека" обеспечил технологический прорыв, который будет питать науку о живом еще много лет - но который также поставил много новых глобальных вопросов перед современными учеными.
http://bioinformaticsinstitute.ru/guests
В пятницу 10 октября в 19.00 Мария Шутова (ИоГЕН РАН) выступала в Институте биоинформатики с открытой лекцией, посвященной изучению рака.
Рак -- одна из наиболее распространенных причин смерти по всему миру. В лекции рассматривается, как знания об эволюции, работе генома, репрограммировании, а также использование биоинформатических методов помогли лучше понять, как развивается раковая опухоль и предложить новые методы лечения разнообразных типов рака. Рассмотрены мышиные модели развития рака и интересные результаты, которые были получены с их помощью.
http://bioinformaticsinstitute.ru/lectures
Гостевая лекция Института биоинформатики, 9 октября 2014. Лектор -- Мария Шутова (ИоГЕН РАН).
За последние десять лет плюрипонтентные клетки стали героями двух Нобелевских премий и многих тысяч научных и научно-популярных статей. Их уникальная возможность превращаться в любую клетку взрослого организма до сих пор дает пищу для ума как биологам развития, так и ученым, ищущим способы лечения генетических заболеваний. В лекции будет рассказано о двух типах плюрипотентных клеток: "естественных" (эмбриональные стволовые клетки) и "искусственных" (индуцированные плюрипотентные стволовые клетки). Отдельно мы остановимся на том, как знания о работе транскрипционных факторов помогли репрограммировать клетки, и как эти "искусственные" плюрипотентные клетки можно использовать в медицине.
В своей лекции Андрей Афанасьев рассказал о стартапах в биотехе и биоинформатике и своем биоинформатическом проекте iBinom, разобрал несколько биотехнологических проектов глазами инноваторов и инвесторов, а также коснулся вопроса поиска инвестиций и поделился личным опытом взаимодействия с венчурными фондами и институтами развития.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
DevOps and Testing slides at DASA ConnectKari Kakkonen
My and Rik Marselis slides at 30.5.2024 DASA Connect conference. We discuss about what is testing, then what is agile testing and finally what is Testing in DevOps. Finally we had lovely workshop with the participants trying to find out different ways to think about quality and testing in different parts of the DevOps infinity loop.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
Key Trends Shaping the Future of Infrastructure.pdfCheryl Hung
Keynote at DIGIT West Expo, Glasgow on 29 May 2024.
Cheryl Hung, ochery.com
Sr Director, Infrastructure Ecosystem, Arm.
The key trends across hardware, cloud and open-source; exploring how these areas are likely to mature and develop over the short and long-term, and then considering how organisations can position themselves to adapt and thrive.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
PHP Frameworks: I want to break free (IPC Berlin 2024)Ralf Eggert
In this presentation, we examine the challenges and limitations of relying too heavily on PHP frameworks in web development. We discuss the history of PHP and its frameworks to understand how this dependence has evolved. The focus will be on providing concrete tips and strategies to reduce reliance on these frameworks, based on real-world examples and practical considerations. The goal is to equip developers with the skills and knowledge to create more flexible and future-proof web applications. We'll explore the importance of maintaining autonomy in a rapidly changing tech landscape and how to make informed decisions in PHP development.
This talk is aimed at encouraging a more independent approach to using PHP frameworks, moving towards a more flexible and future-proof approach to PHP development.
"Impact of front-end architecture on development cost", Viktor TurskyiFwdays
I have heard many times that architecture is not important for the front-end. Also, many times I have seen how developers implement features on the front-end just following the standard rules for a framework and think that this is enough to successfully launch the project, and then the project fails. How to prevent this and what approach to choose? I have launched dozens of complex projects and during the talk we will analyze which approaches have worked for me and which have not.
2. Comparing Fluorescence In SituComparing Fluorescence In Situ
Hybridization and Chromogenic InHybridization and Chromogenic In
Situ Hybridization Methods toSitu Hybridization Methods to
Determine the HER2/neu StatusDetermine the HER2/neu Status
in Primary Breast Carcinomain Primary Breast Carcinoma
using Tissue Microarrayusing Tissue Microarray
Kyeongmee Park, M.D., Ph.D., Jungyeon Kim,
M.D., Ph.D., Sungjig Lim, M.D., Ph.D., Sehwan
Han, M.D., Ph.D., Jung Young Lee, M.D., Ph.D.
Inje University Sanggye Paik Hospital; College of Medicine,Inje University Sanggye Paik Hospital; College of Medicine,
The Catholic University, Seoul, Korea 2003The Catholic University, Seoul, Korea 2003
3. • HER2/neu is the most widely exploited breast
cancer marker in clinical oncology.
• HER2/neu has moved from a laboratory-
based prognostic factor to a target for the
specific therapy, trastuzumab (Herceptin;
Genentech, Inc., South San Francisco, CA),
which binds to HER2/neu protein.
• 185kDa transmembrane tyrosine kinase
• overexpression of HER2/neu protein arises
from HER2/neu gene amplification
4. • 20-40% of human breast carcinomas shows
HER2/neu amplication
• HER2/neu protein overexpression use
immunohistochemistry detect.
• Measurement of HER2/neu gene amplification is
more accurate
• Fluorescence in situ hybridization (FISH) allows
assessment of the level of gene amplification
with information about distribution of gene copies
in histologic section
• FISH need additional equipment for analysis
such as fluorescence microscopy and multiband
fluorescence filters.
5. • Chromogenic in situ hybridization uses a
simple immunohistochemistry-like
peroxidase reaction.
• Tissue microarray is a novel technology of
harvesting small disks of tissue from
individual donor paraffin-embedded tissue
blocks and placing them in a recipient
block with defined array coordinates.
• Tissue microarray technology allows high-
throughput molecular profiling of cancer
from DNA to protein level by enabling the
simultaneous analysis of hundreds of
tissue specimens.
6. • This technology provides maximal use of limited
tissue resources and renders the advantage of
generating gene expression profiles of cells as
they occur in actual neoplastic tissues in vivo.
• Tissue microarray technology has the potential to
significantly accelerate molecular studies and
has become one of the most promising tools in
cancer research fields.
• In this report, analysis of HER2/neu amplification
in 188 human breast carcinomas using tissue
microarray technology. CISH appeared as a
reasonable alternative to FISH in the current
study, and genetic analyses on the archival
cancer tissues were successful with novel
technologies.
7. Materials and Methods
• Materials: 188 primary breast carcinoma were
collected at Inje University Sanggye Paik
Hospital, Seoul, Korea
• Histopathologic classification and determination
of tumor collecting regions were done on HE
stain slide.
• The invasive ductal carcinoma with grade I-III
with the Nottingham histologic grading system in
ascending degree of malignancy and was grade
I-III with the Black’s nuclear grading system in
descending degree of malignancy.
8. Tissue Microarray Block
• Recipient block were made with purified
agar in 3.8 x 2.2 cm. Frames. Holes with
2mm in each size were made on the
recipient blacks by core needle, and agar
core was discarded.
• Donor block were prepared after through
evaluation of HE slides.
• Cancer portions were transplanted to the
recipient blocks using a 2mm core needle.
• Recipient block were framed in the mold
that is used to frame conventional paraffin
block, and then paraffin was added to the
frame.
9. • Consecutive sections in 3.5 µm thickness
were cut from the recipient blocks using an
adhesive-coated slide system supporting
the cohesion of the 2mm array elements
on the glass. (Fig 1)
10. Fig 1. A portion of tissue microarray section of breast
carcinoma (H&E, 10x)
11. Fluorescence In Situ Hybridization
(FISH)
• 3.5µm thick consecutive microarray section
• deparaffinized, dehydrated
• Pretreatment solution
• protease solution
• denaturation solution
• hybridization, 20 µl LSI HER2/CEP17 probe
was applied, & a coverslip applied over the
probe
• Nuclei stained by DAPI
12. • Centromere 17 (CEP) and HER2/neu copy
numbers were estimated for the
predominant tumor cell population.
• Hybridization signals were enumerated by
the ratio of orange signals for HER2/neu to
green signals for CEP im morphologically
intact and nonoverlapping nuclei.
• At least two times more HER2/neu signals
than CEP signals in the tumor cells was
considered as the criterion for HER2/neu
amplification.
13. Fig2. FISH shows increasedHER2/neub gene copy number in
breast cancer tissue (orange:HER2/neu, green: CEP control)
15. • Incubated 37 overnight; wash;100℃ µl
CAS-Block (Zymed) FITC-sheep anti-
digoxigenin (Zymed)
• 100 µl HRP-goat anti-FITC (Zymed) 30-60
mins
• 150 µl 3,3-diaminobenzidine
tetrahydrochloride 20-30 min
• microarray slides were counterstained with
hematoxylin and eosin
• dehydration with ethanol and xylene
• HER2/neu amplification:gene copy number
>4 or large gene copy cluster was seen in
>50% of cancer cell nuclei
16. Fig 3. CISH with amplification of HER2/neu gene
17. Data Analysis
• χ² test was used for data analysis, and
correlation between the results was
estimated by Spearman’s correlation
coefficient (κ)
• κ value ⇒1– complete agreement
• κ value ⇒7.5– excellent agreement
• κ value ⇒0.4-0.75– fairly good
agreement
• κ value ⇒<0.4– poor agreement
18.
19. Results
• HER2/neu amplification was detected in 46
cases (24.5%) by FISH and in 42 (22.9%) of
188 by CISH
• Results of each method agreed with each
other in 177 cases (94.1%) (Table 1)
• Between the two methods, κ value was 0.838.
• The results of the study indicated that
efficiency of the two methods was equivalent
to each other.
20. • Among the 178 invasive ductal carcinoma,
HER2/neu amplification by FISH and CISH
was associated with poor nuclear grade
(p=.043 & .037). However, it was not
associated with histologic grade.
• Nuclear pleomorphism was associated with
HER2/neu amplification by FISH. (p=.021).
However, it was not associated with
HER2/neu amplification by CISH. (p=.064).
• No significant association with found
between tubule formation or mitotic counts
and HER2/neu amplification (Table 2 & 3)
21.
22. Discussion
• A significant correlation between CISH and
FISH in the current study with high
concordance rate.
• High concordance seems to be partly
influenced by the advantage of tissue
microarray technology.
• The current study indicated that tissue
microarray technology was feasible for
assaying gene amplification with a limited
tissue volume.
• Used 2mm sized needle for collecting
microarray panels.(originally was developed
that is as small as 0.6 mm in diameter)
23. • Heterogeneity of the breast carcinoma
sometimes makes it difficult to accurately
analyze the biologic properties of individual
cancers, especially in antigens with
heterogeneous staining patterns.
• Applied a large needle of 2mm size in
collecting the microarray panels to minimize
the inadvertent variation in results from tumor
heterogeneity.
• Tissue microarray analysis had a merit: it
could be performed in consecutive sections
that had the same cancer tissues in the same
coordinate positions as the others.
24. • A main obstacle to the popularization of FISH
analysis has been the need to use special
fluorescence microscopy with multi-bandpass
fluorescence filters that makes it difficult for
most institutes to integrate FISH in routine
clinical diagnostics.
• The practical superiority of CISH over FISH in
the assessment of gene amplification.
• CISH does not require equipment that does
not already exist in routine pathologic
laboratories.
• another advantage is that simultaneous
verification of histology can be done with
CISH.
25. • CISH can be used instead of FISH in the
screening of HER2/neu amplification in the
primary breast carcinomas with feasibility and
relative cost-effectiveness.
• Prevalence of HER2/neu amplification was
22.9% by CISH and 24.5% by FISH, which
well coincides with the results of other
studies.
• The validity of tissue microarray analysis has
been shown by comparisons with whole-
section analysis in breast carcinoma.
• The main purpose in analyzing HER2/neu
status is to provide the most effective
therapeutic regimens for breast cancer
patients.
26. • Recently, an interesting report
performed FISH and RNA-RNA in situ
hybridization for HER2/neu on the same
cancer tissues. Results of that study
indicated that mRNA expression was
highly concordant with FISH and that
most cases of immunohistochemistry
positive without gene amplification in
FISH were devoid of mRNA expression.
• Hence, those investigators suggested
that such cases were most l false
positive and non-specific.
27. • Results from most studies comparing
FISH and IHC have indicated that FISH
was superior to all other methodologies in
assessing formalin-fixed, paraffin-
embedded material for HER2/neu
amplification.
• Data from the current study indicate that
tissue microarray analysis is a feasible
and reliable method for assessing
HER2/neu amplification with rapidity in a
large number of tissue.
28. • CISH can be a tempting alternative to FISH
because of its accuracy and relative low cost.
• CISH with tissue microarray technology
enables high-throughput determination of
HER2/neu expression profile and its
abnormalities in large cohorts of breast
carcinoma.
• Integration of two novel technologies can
provide a rapid validation of identified
predictive markers in other cancer research
fields.